TenCore Partners LP Takes Position in Enfusion, Inc. (NYSE:ENFN)

TenCore Partners LP purchased a new stake in Enfusion, Inc. (NYSE:ENFN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 414,982 shares of the company's stock, valued at approximately $3,938,000. Enfusion accounts for approximately 1.9% of TenCore Partners LP's holdings, making the stock its 11th largest holding. TenCore Partners LP owned approximately 0.32% of Enfusion as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. RiverPark Advisors LLC acquired a new stake in Enfusion during the 2nd quarter worth approximately $68,000. Arizona State Retirement System acquired a new stake in shares of Enfusion in the 2nd quarter valued at approximately $86,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Enfusion during the 1st quarter worth $102,000. Harbor Capital Advisors Inc. increased its holdings in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Finally, Belvedere Trading LLC acquired a new stake in shares of Enfusion in the third quarter valued at about $114,000. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Stock Performance

NYSE ENFN traded up $0.16 during mid-day trading on Friday, reaching $10.16. 216,141 shares of the stock were exchanged, compared to its average volume of 381,998. The stock has a market capitalization of $1.31 billion, a PE ratio of 250.13, a PEG ratio of 3.79 and a beta of 0.97. The business's fifty day simple moving average is $9.37 and its 200 day simple moving average is $8.91. Enfusion, Inc. has a 1-year low of $7.52 and a 1-year high of $10.40.

Insider Activity

In other news, COO Neal Pawar sold 21,801 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 36.44% of the company's stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.